20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...
19:10 , Oct 26, 2018 |  BC Week In Review  |  Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
16:36 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
13:07 , Oct 24, 2018 |  BC Extra  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
16:06 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Oyster Point's OC-02 nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the double-blind, U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point...
21:34 , Jul 12, 2018 |  BC Extra  |  Clinical News

Oyster Point's nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point plans...
15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Axsome raises $9.5M in direct offering

CNS company Axsome Therapeutics Inc. (NASDAQ:AXSM) raised $9.5 million through the sale of 1.8 million units at $5.33 in a registered direct offering led by HC Wainwright. Each unit represents one share of common stock...